Engineered immune cells take aim at tough leukemia
NCT ID NCT07257640
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tests a new treatment called IL-5 CAR-T cell therapy for people with a rare and hard-to-treat blood cancer called eosinophilic leukemia. The therapy uses a patient's own immune cells, modified to target and attack cancer cells. The main goals are to check safety and see if the treatment can shrink or control the cancer.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EOSINOPHILIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The first affiliated hospital of medical college of zhejiang university
RECRUITINGHangzhou, Zhejiang, 310003, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could muscle loss predict blood cancer outcomes?
- A simple screening program could transform cancer aftercare
- A new program aims to ease the 'Lost in Transition' struggle for cancer survivors
- Can a new immune drug outsmart Hard-to-Treat tumors?
- Can a simple text message transform cancer care?
- Can modern Radiotherapy's late effects be predicted?